{"name":"NicOx","slug":"nicox","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AC-170 Vehicle","genericName":"AC-170 Vehicle","slug":"ac-170-vehicle","indication":"Ocular hypertension or glaucoma (Phase 3 development)","status":"phase_3"},{"name":"NCX 470 0.1%","genericName":"NCX 470 0.1%","slug":"ncx-470-0-1","indication":"Open-angle glaucoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Carmellose","genericName":"Carmellose","slug":"carmellose","indication":"Other","status":"discontinued"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Iota-Carrageenan","genericName":"Iota-Carrageenan","slug":"iota-carrageenan","indication":"Prevention and treatment of common cold caused by rhinoviruses and other respiratory viruses","status":"marketed"}]}],"pipeline":[{"name":"AC-170 Vehicle","genericName":"AC-170 Vehicle","slug":"ac-170-vehicle","phase":"phase_3","mechanism":"AC-170 Vehicle is a formulation component designed to deliver the active pharmaceutical ingredient AC-170 to ocular tissues.","indications":["Ocular hypertension or glaucoma (Phase 3 development)"],"catalyst":""},{"name":"Carmellose","genericName":"Carmellose","slug":"carmellose","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Iota-Carrageenan","genericName":"Iota-Carrageenan","slug":"iota-carrageenan","phase":"marketed","mechanism":"Iota-carrageenan is a natural polysaccharide that forms a protective physical barrier on nasal mucosa to trap and prevent viral particles from infecting respiratory epithelial cells.","indications":["Prevention and treatment of common cold caused by rhinoviruses and other respiratory viruses"],"catalyst":""},{"name":"NCX 470 0.1%","genericName":"NCX 470 0.1%","slug":"ncx-470-0-1","phase":"phase_3","mechanism":"NCX 470 is a nitric oxide-donating prostaglandin F analog that lowers intraocular pressure by increasing uveoscleral outflow and releasing nitric oxide to enhance trabecular outflow.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQbk91SWw5cmEtMzhiRXhJNmRsVnpBaWhfcXg0T0h5Szh4Tm1zSGk0V1h1emxUcVRmaVgyczdpM1ZXXzJFYVBvWXRuNGpXckd1NjJzWmU0ZVFNMmpJSFl6dTFDR0I3Zzk0VURWZmo0bGl1Zl9hbHhOY1k3elhSNXlXM09HeDlMNk5mSFlZajQxSDctOGl5c0ZtYm9fbnZ6aEU?oc=5","date":"2026-04-03","type":"earnings","source":"openPR.com","summary":"Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034 - openPR.com","headline":"Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOc0lRZEE0b2RVSmRqMW1EMGdpTnBBclduaFBYNk94V1BxMjJrMU52SGFabHV5UTVnQmpHNFJkbElvTFBESGtaN01QUEpzejlHSDlDR0JUQllNNElLYzRILTZDQi1IY0dNQWU4aGE5bVdpWXBNaTJTYkNWdU4zWTRXb1U4WDZYRmp3Nl9NekxOQzVxZnhFcGZYSE0wdExxMF83ZldiWERJeTFIZEUwcW5NTlpGaWpsNUsy?oc=5","date":"2025-09-03","type":"trial","source":"Eyes On Eyecare","summary":"Nicox reports positive phase 3 data on NCX 470 glaucoma eye drop - Eyes On Eyecare","headline":"Nicox reports positive phase 3 data on NCX 470 glaucoma eye drop","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPRzdSbG9ObXhXanFUN3hpYnhybllVLXltaS1YeVU4dTA0b0ZJZjhPVGYxdjFkY2N6cnZhb0JGckEyT0V4c1NuSWxtYTFlZkNxUlFzc0JYdDJtaXBFdmswVnZrWW9zVHhvMDZOTlNkalpYZXFLT3dHVDNSTHBpakNqSVFR?oc=5","date":"2025-08-21","type":"trial","source":"pharmaphorum","summary":"Nicox plans filings for glaucoma after phase 3 win - pharmaphorum","headline":"Nicox plans filings for glaucoma after phase 3 win","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9oRS03Y2x2OFpWTTRqV0E3YkRVYVJVYkdTVklSREl6Q3RLMGdsaXBQTFBUeWRTdWlWT010RUhMWklYUmFzWGdvYXk4MnVoQkxHQzRB?oc=5","date":"2025-08-21","type":"trial","source":"FirstWord Pharma","summary":"Nicox eyes US, China filings after glaucoma eye drop scores second Phase III win - FirstWord Pharma","headline":"Nicox eyes US, China filings after glaucoma eye drop scores second Phase III win","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdWd3MTluVC12QmF3MGVUaGhSWnBqLVJwZE13NG9vSm5CN0JkWUNWVWd3M1h5bFl0MFZoZUpFUTR4NXZOcjE2OXVfUjNwX1JHSGRTcE1sNUphanZfTUtZZk5taTdwVUVsMzJjNWZiUjNCaXVhbmY4MEJqdktkTFRFa1ZTaUhIRVFNXzJzRVowcVJFdmtWS1diOUc4WE5PVG5pdTJqSlozNHBjT3c?oc=5","date":"2025-08-19","type":"deal","source":"BioSpectrum Asia","summary":"Nicox and Kowa sign €191.5 M deal for glaucoma treatment - BioSpectrum Asia","headline":"Nicox and Kowa sign €191.5 M deal for glaucoma treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOWGJrTEl1NzJPWXl3c0RWa01yOEZqRkh1dzJMWVJzUTdrRGg3SUJpNGZDYktnYVk1eTZ2Q1E3bEExN2pFSjkyNjlMaEtxMGtsRHhJNEU4WC13UDVYaVJlaEY2TGpXcDNNS09SUk1KY3NTUDB2bXNBTF8wX0lwbzY1NDBTaHdQSk1YYUpqMldDb3QweEdWX3kzYTJ4WkZBM000Nzc4ajRyQkpUVlpkQ3daS29QSTBOQkp6cG16Zw?oc=5","date":"2025-07-20","type":"pipeline","source":"Ophthalmology Times","summary":"Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470 - Ophthalmology Times","headline":"Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNTERJZ25jc1NPd3BYMzBNc3k1RUttSWdxNUVVUzRiUVNtZUJjTGljTTNEN0lLNkItQklPeWx4cWJWS29wSXpuWXZzSFkydE05eVVmamJna2RHaEFONHRMTld6MGoxTlZJcWNmdFUyMFA4aU5UbVJnalM1NDMyT0VUSk40MHlDTm1kdXE4SXZ2ZkNWcmZmU0xBM3I2Wm9nYTBlNjlGMEtIQVZ5aWhpYnc?oc=5","date":"2025-07-18","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—China biotech deal boom; Takeda's narcolepsy win; Sino Biopharm's LaNova buyout - Fierce Pharma","headline":"Fierce Pharma Asia—China biotech deal boom; Takeda's narcolepsy win; Sino Biopharm's LaNova buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFB4SnUxNmsyMWpicGZzbzNzalJMcWxzUHBPNlJtTXZhc0ladkwwLTl3cWtNUXZyVmU1Ni10YnI0MXVTZ3JhVzU2cVRuSHZJd1M4amRN?oc=5","date":"2025-07-17","type":"pipeline","source":"FirstWord Pharma","summary":"Kowa secures expanded rights to Nicox's glaucoma drug in key markets - FirstWord Pharma","headline":"Kowa secures expanded rights to Nicox's glaucoma drug in key markets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE05OGRkOWFVSkVyeDd5RTRVbXF3N0FkUDlRblhYY1ZxTlRzWUxLa1lTRm9LX1g3X0VIQ3N1a2VMX2h1VnBieGhGZXE1LWxJNE5LV255aWN3Y0s4VnRXd0g3UA?oc=5","date":"2024-03-26","type":"pipeline","source":"PharmaTimes","summary":"Gavin Spencer - PharmaTimes","headline":"Gavin Spencer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNVUwwYlVNc0hkdW5naGdqZFNFaUF4V0NQdGN3NDFPNHZPZExmSm1ucDBZQzY3Z3BNUWdzVmExNmhydmpoVU5iN2VQWWMxcndDd0VOUWw5Mm1jbDhVRkFFT2t4OGlLRE5iaXFlOFdHVHZKNHJEcTR3UXdjN0JpR1lJdVNLd2ptdVFZNERUTEs4WHlGZ3hyOFE?oc=5","date":"2022-02-22","type":"regulatory","source":"Yahoo Finance UK","summary":"Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries - Yahoo Finance UK","headline":"Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOZ1l4X3czWXpzb2MyWU9wM2RNWUVQTm00Um1jNGtzYXh6c3ZEdjIzWFREbWY5cWhWaVNDci1aYm1XNlRvOVAyYVFTNEVjRUxjMVZOZGZlYktOMWpwYXpHaGp5VzNIZzJoMVpZTGdBZ3EwMUpmRFFzMlhUeEN1Wi1HNkpXV1d3dWdoSllyenVBVWtFWnFyc0I2OXEzRFhIM2pYaG02RG5LTXNCSmZMOGxlUFRvNW8wcmlkOXJTMGY5NFRjaVJ6aFhBTHNVeGtDTkxTVHFmTEZ1S0lzUTRhOEtndkI4Nk9OY2FiRWpYdDVB?oc=5","date":"2017-11-02","type":"regulatory","source":"PR Newswire","summary":"Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (Latanoprostene Bunod Ophthalmic Solution), 0.024% - PR Newswire","headline":"Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (Latanoprostene Bunod Ophthalmic Solution), 0.024%","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9vS2hSSHNpeTVFVjdNM09peVFYQ1BqdjhSV2hPcklRY3ZUeFYxMnFwOURSRHh3WHBmSG5vRFk4dk8zWHBuQ3pHNnNlbXluYm5SM0FLTDB6d0t5MHlmYzhNVlpYT1JqQ0lLYzY3VjhseXdZUWx2SEpDM0xDbw?oc=5","date":"2017-08-17","type":"pipeline","source":"Fierce Biotech","summary":"EuroBiotech—More articles of note - Fierce Biotech","headline":"EuroBiotech—More articles of note","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"discontinued":1,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}